Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2018-001292-21-FR (EUCTR)	27/07/2018	05/06/2018	Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years	Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years	Secondary Progressive Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10063400;Term: Secondary progressive multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: AVONEX Product Name: BETAFERON Product Code: L03 AB 08 Product Name: EXTAVIA Product Name: REBIF Product Name: PLEDIGRY Product Name: COPAXONE Product Name: AUBAGIO Product Name: TECFIDERA Product Name: GILENYA Product Name: TYSABRI Product Name: IMUREL Product Name: NOVATREX Product Name: CELLCEPT Product Name: ENDOXAN	CHU de Rennes	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	250	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	France
2	EUCTR2009-015502-19-GB (EUCTR)	08/02/2010	17/03/2010	A multinational, multicenter, single visit, exploratory pharmacogenetic trial and long-term follow-up of the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) trial - PRISMS-15	A multinational, multicenter, single visit, exploratory pharmacogenetic trial and long-term follow-up of the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) trial - PRISMS-15	Multiple Sclerosis MedDRA version: 12.0;Level: PT;Classification code 10028245;Term: Multiple sclerosis	Trade Name: Rebif Product Name: Rebif Product Code: L03 AB07 Other descriptive name: INTERFERON BETA -1A	Merck Serono SA – Geneva	NULL	Not Recruiting	Female: yes Male: yes	300		Finland;Germany;United Kingdom;Belgium;Sweden
3	EUCTR2008-006226-34-BE (EUCTR)	23/12/2009	29/09/2009	A multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis plus a long-term extension period. - TENERE	A multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis plus a long-term extension period. - TENERE	Multiple sclerosis	Product Name: Teriflunomide Product Code: HMR1726 INN or Proposed INN: Teriflunomide Product Name: Teriflunomide Product Code: HMR1726 INN or Proposed INN: Teriflunomide Trade Name: Rebif INN or Proposed INN: INTERFERON BETA -1A Trade Name: Rebif Product Code: L03 AB INN or Proposed INN: INTERFERON BETA -1A Trade Name: Rebif Product Name: L03 AB INN or Proposed INN: INTERFERON BETA -1A	sanofi-aventis recherche et development	NULL	Not Recruiting	Female: yes Male: yes	300		France;Czech Republic;Hungary;Spain;Belgium;Germany;United Kingdom;Italy